Print
Email
Print Edition Stories
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Epizyme Inc., has raised an additional $8 million dollars to close out a series B financing totalling $40 million. The Cambridge-based company had announced in September that it had raised $32 million.
The $8 million comes from a single investor, New Enterprise Associates. NEA joins an investor group that includes BCC, Amgen Ventures, Astellas Venture, MPM Capital and Kleiner Perkins Caufield and Byers (KPCB). Coincident with the second close of the Series B financing, David M. Mott, NEA General Partner, joins the company’s board of directors.
“Expanding our syndicate to include NEA adds another investor with significant drug-development and company building expertise as well as substantial capital resources,” said Epizyme CEO Kazumi Shiosaki in a statement. “By raising more capital now, we can continue to aggressively advance our pipeline of histone methyltransferase inhibitors for various oncology indications.”
Epigenetic enzymes are thought to play roles in various diseases including cancer, inflammatory conditions, metabolic disorders and neurological and psychiatric diseases. Epizyme is developing a technology platform that will help identify inhibitors of these enzymes, and then try to figure out how they can be used to fight a variety of diseases.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
